[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 4 sources · 8 days · First seen · Last updated

Prostate cancer detection and treatment advancements

Overview

Medical research and clinical guidance regarding prostate cancer have focused on improving early detection and personalizing treatment strategies.

Researchers at Moffitt Cancer Center and Oxford University have developed mathematical biomarkers, such as the Adaptive Therapy Score (AT Score) and Expected Time to Progression (eTTP), to assist in adaptive therapy. This approach uses data from routine prostate-specific antigen (PSA) blood tests to help physicians determine when to pause or restart treatment, aiming to slow the growth of drug-resistant cells.

In parallel, medical experts emphasize the necessity of early screening to identify the disease before symptoms like urinary discomfort or bone pain emerge. While the PSA test remains a primary diagnostic tool, recent innovations are directed toward more precise tumor identification and individualized care to improve patient outcomes.

Entities

Cristián Urzúa · Corporación Chilena Contra el Cáncer de Próstata · JAMA Oncology · Felipe Balbontín Fox · Oxford University

Timeline

  1. 23 days ago

    [HEALTH] 4 sources
    Prostate cancer detection and treatment advancements

    Medical experts highlight the importance of early prostate cancer detection through PSA testing and emphasize that new diagnostic innovations are enabling more personalized and effective treatments.

  2. about 1 month ago

    [HEALTH] 2 sources
    Moffitt Cancer Center researchers develop biomarkers for prostate cancer therapy

    Moffitt Cancer Center researchers developed mathematical biomarkers using routine blood tests to help doctors personalize adaptive prostate cancer therapies and predict patient outcomes.

Sources

diariodelsur.com.co · elreferente.cl · hsbnoticias.com · panamaamerica.com.pa